Preclinical and clinical issues in Alzheimer's disease drug research and development by Cesare Mancuso & Silvana Gaetani
EDITORIAL
published: 28 October 2014
doi: 10.3389/fphar.2014.00234
Preclinical and clinical issues in Alzheimer’s disease drug
research and development
Cesare Mancuso1* and Silvana Gaetani2
1 Institute of Pharmacology, Catholic University School of Medicine, Rome, Italy
2 Department of Physiology and Pharmacology “Vittorio Erspamer,” Sapienza University of Rome, Rome, Italy
*Correspondence: cmancuso@rm.unicatt.it
Edited and reviewed by:
Salvatore Salomone, Catania University, Italy
Keywords: Alzheimer’s disease, preclinical studies, clinical trials as topic, drug research and development, neurodegeneration
Alzheimer’s disease (AD) is a chronic, rapidly progressive neu-
rodegenerative disease, characterized by loss of memory and
cognitive abilities, inability to carry out regular daily activities
and mental disorders. The following numbers provide an idea
of the extent of the problem: 36 million people worldwide suf-
fer from dementia, of which 7.7 million new cases each year, and
60–70% of them are diagnosed with AD. Patients with AD deal
with numerous problems, one of the most relevant being the lack
of drugs that can slow down or hinder disease onset. Indeed, the
currently available drugs, namely acetylcholinesterase inhibitors
donepezil, rivastigmine, and galantamine, and the NMDA recep-
tor antagonist, memantine, are able to counteract or delay the
symptoms related to cognitive decline and nearly entirely in
individuals with mild-to-moderate AD. The shortage of drugs
available for the treatment of AD is also related to the difficul-
ties faced by many pharmaceutical companies, including some
Big Pharma, that despite significant achievements from their
hit/leads in preclinical and early stages of clinical research, have
not been able in recent years, to launch their products on the
market due to ineffective results in terms of efficacy or safety of
advanced clinical trials. This problem is at least in part due to
investigators’ difficulties in identifying the most adequate out-
comes in order to plan clinical trials. Indeed, in many cases,
attention has been focused on certain plasma or cerebral-spinal
fluid (CSF) biomarkers, both for the relative ease of sampling and
for the possibility they could offer to monitor the disease pro-
gression. However, it is worth emphasizing, that despite clinical
trials based on the use of peripheral biomarkers have provided
encouraging results on the ability of some drugs to block the
production or deposition of β-amyloid (Aß) or even destroy exist-
ing senile plaques, key phase III studies, specifically designed to
evaluate the improvement of cognitive activity, have shown a
reduced ability of these new molecules to enhance memory or
the ability to perform regular daily living functions in patients
with AD or, in some cases have also resulted in severe side
effects. Another limitation of pharmacological research on AD
is the scarce ability to enhance collaboration between pharma-
ceutical industries and public or private non-profit organizations
conducting basic research, such as universities. Both these sec-
tors would benefit from the strengthening of this cooperation
allowing non-profit institutions to enhance basic research on
AD by receiving funds from pharmaceutical companies that,
in turn, could benefit from the research of qualified scientists
worldwide.
This Research Topic has been designed as a platform to analyze
some of the most relevant problems posed by research on AD,
suggest and develop new ideas that may improve both preclinical
and clinical research on this disease. This Research Topic in which
leading experts in the field of AD have contributed, is organized
in 5 review articles, 3 original research articles, 1 opinion article,
1 Perspective article and 1 Commentary.
The complexity of the events that determine the onset and
progression of AD is emphasized by the many factors that con-
tribute to the pathogenesis of this disease. Recently, what has been
pointed out is the pathogenetic role played by posttranslational
modifications, such SUMOylation, on proteins involved in the
production of Aß (Nisticò et al., 2014). In light of this, it is worth
noting the remarkable discovery in Tg2576 transgenic mice, a
validated preclinical model for the study of AD, that the imbal-
ance of the phenomena of protein SUMOylation/deSUMOylation
occurs in cognitive brain areas, such as the hippocampus and cor-
tex, in the very early stages of the disease. This finding certainly
contributes to indicate an alternative target for the development
of new drugs for AD (Nisticò et al., 2014). The importance of
having predictive preclinical models for the proper study of AD
is also pointed out by Davis and Head (2014) who suggest the
aged canine as an useful animal species for studies on AD and
as an alternative to rodent models. Indeed, it has been shown
that elderly beagle dogs have a progressive loss of cognitive func-
tions with age and they show characteristic neuropathological
hallmarks of AD (Davis and Head, 2014). This canine model
allowed preclinical studies on the role of neuroprotective drugs,
such as statins. An interesting link between the pathogenesis of
AD and of other, apparently different, diseases, such as glau-
coma, has been highlighted in a study by Trovato Salinaro et al.
(2014). In fact, both AD and glaucoma have a common patho-
genetic role played by free radicals and the ability to activate
the adaptive stress response systemically (Trovato Salinaro et al.,
2014). As in many cells, the activation of cell stress response is a
response mechanism to the damage caused by free radicals and its
modulation by nutritional supplements, defined nutraceuticals, is
currently considered an adjuvant approach to standard therapy
of diseases, including AD (Mecocci et al., 2014). The results by
Scuderi et al. (2014) seem to support this theory, showing that
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the up-regulation of the sirtuin system, via resveratrol, is able to
reduce the activation of astrocytes and the production of inflam-
matory mediators in primary cultures of rat astrocytes treated
with Aß(1–42). The causal role of infectious agents in relation to
the pathogenesis of AD has been little experimented. As reported
by Piacentini et al. (2014), recurrent infection by herpes simplex
virus type I (HSV-1) can be considered a risk factor for AD. The
mechanism(s) through whichHSV-1 could give rise to AD are not
completely understood, even if the HSV-1–mediated proteolytic
processing of APP, generating also Aβ40 and Aβ42 monomers
or small oligomers, is among those which received the greatest
consensus (Piacentini et al., 2014).
Among the issues with the highest translational impact on
research in the field of AD is the use of “old” drugs such as vita-
min D, currently used for years in the treatment of bone loss,
above all in the elderly, whose neuroprotective properties in sub-
jects with AD have been recently brought to light (Annweiler
et al., 2014). A very updated and comprehensive review arti-
cle by Cornelius et al. (2014) examines the factors that can be
considered as a common denominator of AD and osteoporo-
sis. The dysregulation of the endocannabinoid system, initially
based on a number of preclinical evidence, as a viable mechanism
to intervene in the pathogenesis of AD is no longer contro-
versial (Aso and Ferrer, 2014). Furthermore, the availability of
“new” pharmacological tools to modulate the endocannabinoid
system of the brain, one with the preclinical evidence of their
effectiveness in terms of a significant reduction of oxidative and
metabolic damage load on neurons and objective improvements
of behavior in individuals with AD, leads research further toward
the study of the endocannabinoid system as a novel therapeu-
tic target in AD (Aso and Ferrer, 2014). An example of how
a virtuous collaboration between non-profit institutions, such
as universities, and pharmaceutical companies should develop
is in the article by Lundkvist et al. (2014). This paper focuses
on the activities of “AlzeCure,” a non-profit Swedish foundation
founded by brilliant researchers with a strong background in
R&D from a Big Pharma such as Astra Zeneca. The AlzeCure acts
as a catalyst, receiving continuous feedback from biotech compa-
nies, and leading academic institutions (e.g., Karolinska Institute)
involved in R&D of drugs for AD, collaborating in the preclin-
ical and clinical field, demonstrating that a useful collaboration
between non-profit institutions and pharmaceutical companies
is actually possible (Lundkvist et al., 2014). A viable alterna-
tive to this model of academic-industry cooperation is the one
proposed by Beauchet et al. (2014) who, in their Commentary,
described the activities of “Biomathics,” an emerging scientific
research consortiumwhose task is to promote cooperation among
the academic research teams working in the field of aging and
longevity. One of the main goals of this Consortium is to fos-
ter the creation of large research groups, formed by scientists
worldwide, so as to increase the possibility of applying and
obtaining research grants to enhance international basic research
(Beauchet et al., 2014).
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